Becker's Healthcare April 24, 2024
More than $38 billion was spent in the U.S. on Ozempic and Wegovy (semaglutide) in 2023 — a 100% uptick from 2022 expenditure data, according to research published April 24 in the American Journal of Health-System Pharmacy.
Tirzepatide, the active pharmaceutical ingredient for Mounjaro and Zepbound, increased in popularity by 373% in one year. These four medications are all glucagon-like peptide-1 receptor agonists; and Zepbound is also a glucose-dependent insulinotropic polypeptide.
GLP-1s, which are approved for Type 2 diabetes, weight loss and cardiovascular problems, are part of a booming industry. The manufacturer of Ozempic and Mounjaro, Novo Nordisk, recently became and has remained Europe’s most valuable public company.
The research calculated healthcare drug expenditure among three factors:...
Today's Sponsors
Today's Sponsor